About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNANCT06663618

Short-term Glucocorticoid Combined with MMF for IgG4-RD

Comparison of short-term glucocorticoid monotherapy and short-term glucocorticoid combined with MMF in the treatment of IgG4 Related Disease

Lead sponsor: Wen Zhang•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Linyi Peng, MD

CONTACT

8615810395901 drpenglinyi@163.com

Sponsors

Lead Sponsor

Wen Zhang

This is a monocenter, 72-week prospective, randomized controlled study to compare short-term glucocorticoid monotherapy and short-term glucocorticoid combined with MMF in the treatment of IgG4 Related Disease.

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. 18-80 years old;
•2. All patients must meet the comprehensive diagnostic criteria of IgG4-RD revised in Japan in 2020 or the classification criteria of IgG4-RD formulated by ACR/EULAR in 2019;
•3. Active IgG4-RD (at least one organ has an IgG4-RD reaction score \>=2 at the time of enrollment.)；
•4. No previous medication or recurrence after withdrawal.

Exclusion Criteria

•1. Combined with other autoimmune diseases as the main diagnosis.
•2. Pregnant or lactating women
•3. Patients with malignant tumor
•4. Active bacterial, fungal, viral or mycobacterial infections.
•5. Severe complications of important organs, and the expected survival time is less than 6 months.

Related studies

RECRUITINGPhase 2

A Study of Efgartigimod in Patients With IgG4-Related Disease

NCT07025330 · IgG4-related Disease

RECRUITINGPhase 1

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

NCT06978647 · Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), and more

RECRUITINGEARLY Phase 1

Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease

NCT06497361 · Lupus Nephritis, IgG4-related Disease

RECRUITINGPhase 2

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

NCT06285539 · Behcet's Disease, Idiopathic Inflammatory Myopathies, and more

Meir Medical Center Rheumatologic Biobank

NCT03473912 · Rheumatoid Arthritis, Lupus Erythematosus, Systemic, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 29, 2024Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment63

Start dateSep 2023

Last updatedOct 29, 2024

Condition

IgG4-related Disease

Locations shown

Peking Union Medical College Hospital

Beijing, Beijing Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 29, 2024Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions